Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

[Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system].

Auernhammer CJ, Spitzweg C, Böck S, Knösel T, Bartenstein P.

Dtsch Med Wochenschr. 2019 Oct;144(20):1390-1395. doi: 10.1055/a-0801-3686. Epub 2019 Oct 8. German.

PMID:
31594011
2.

Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors.

Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, Spitzweg C, Boeck S, Unterrainer M, Gildehaus FJ, Böning G, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Bartenstein P.

Eur J Nucl Med Mol Imaging. 2019 Sep 6. doi: 10.1007/s00259-019-04501-6. [Epub ahead of print]

PMID:
31492994
3.

Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy.

Wenter V, Jellinek A, Unterrainer M, Ahmaddy F, Lehner S, Albert NL, Bartenstein P, Knösel T, Spitzweg C, Ilhan H, Todica A.

Eur J Nucl Med Mol Imaging. 2019 Aug 13. doi: 10.1007/s00259-019-04456-8. [Epub ahead of print]

PMID:
31410542
4.

Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival.

Rudisile S, Gosewisch A, Wenter V, Unterrainer M, Böning G, Gildehaus FJ, Fendler WP, Auernhammer CJ, Spitzweg C, Bartenstein P, Todica A, Ilhan H.

BMC Cancer. 2019 Aug 8;19(1):788. doi: 10.1186/s12885-019-6000-y.

5.

Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures.

Fankhauser M, Bechmann N, Lauseker M, Goncalves J, Favier J, Klink B, William D, Gieldon L, Maurer J, Spöttl G, Rank P, Knösel T, Orth M, Ziegler CG, Aristizabal Prada ET, Rubinstein G, Fassnacht M, Spitzweg C, Grossman AB, Pacak K, Beuschlein F, Bornstein SR, Eisenhofer G, Auernhammer CJ, Reincke M, Nölting S.

Endocrinology. 2019 Nov 1;160(11):2600-2617. doi: 10.1210/en.2019-00410.

PMID:
31322702
6.

Radiation-Induced Amplification of TGFB1-Induced Mesenchymal Stem Cell-Mediated Sodium Iodide Symporter (NIS) Gene 131I Therapy.

Schug C, Kitzberger C, Sievert W, Spellerberg R, Tutter M, Schmohl KA, Eberlein B, Biedermann T, Steiger K, Zach C, Schwaiger M, Multhoff G, Wagner E, Nelson PJ, Spitzweg C.

Clin Cancer Res. 2019 Oct 1;25(19):5997-6008. doi: 10.1158/1078-0432.CCR-18-4092. Epub 2019 Jun 13.

PMID:
31196853
7.

Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors.

Bösch F, Bazhin AV, Heublein S, Brüwer K, Knösel T, Reiter FP, Auernhammer CJ, Guba MO, Spitzweg C, Werner J, Angele MK.

BMC Cancer. 2019 Jun 13;19(1):575. doi: 10.1186/s12885-019-5794-y.

8.

Tetrac as an anti-angiogenic agent in cancer.

Schmohl KA, Nelson PJ, Spitzweg C.

Endocr Relat Cancer. 2019 Jun 1;26(6):R287-R304. doi: 10.1530/ERC-19-0058. Review.

PMID:
31063970
9.

[Thyroid nodules: What now?]

Ladurner R, Hallfeldt K, Angele M, Werner J, Reincke M, Spitzweg C, Lottspeich C.

MMW Fortschr Med. 2019 Apr;161(7):38-43. doi: 10.1007/s15006-019-0406-y. Review. German. No abstract available.

PMID:
30989520
10.

Dual-targeted NIS polyplexes-a theranostic strategy toward tumors with heterogeneous receptor expression.

Urnauer S, Schmohl KA, Tutter M, Schug C, Schwenk N, Morys S, Ziegler S, Bartenstein P, Clevert DA, Wagner E, Spitzweg C.

Gene Ther. 2019 Apr;26(3-4):93-108. doi: 10.1038/s41434-019-0059-6. Epub 2019 Jan 25.

PMID:
30683895
11.

Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.

Bösch F, Brüwer K, Altendorf-Hofmann A, Auernhammer CJ, Spitzweg C, Westphalen CB, Boeck S, Schubert-Fritschle G, Werner J, Heinemann V, Kirchner T, Angele M, Knösel T.

Endocr Relat Cancer. 2019 Mar 1;26(3):293-301. doi: 10.1530/ERC-18-0494.

PMID:
30608901
12.

[Erratum to: Hypothyroidism-when and how to treat?]

Koehler VF, Reincke M, Spitzweg C.

Internist (Berl). 2019 Jan;60(1):108. doi: 10.1007/s00108-018-0520-4. German. No abstract available.

PMID:
30361741
13.

Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT.

Kunz WG, Eschbach RS, Stahl R, Kazmierczak PM, Bartenstein P, Rominger A, Auernhammer CJ, Spitzweg C, Ricke J, Cyran CC.

Cancer Imaging. 2018 Sep 20;18(1):34. doi: 10.1186/s40644-018-0168-2.

14.

A Novel Approach for Image-Guided 131I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene Delivery.

Schug C, Gupta A, Urnauer S, Steiger K, Cheung PF, Neander C, Savvatakis K, Schmohl KA, Trajkovic-Arsic M, Schwenk N, Schwaiger M, Nelson PJ, Siveke JT, Spitzweg C.

Mol Cancer Res. 2019 Jan;17(1):310-320. doi: 10.1158/1541-7786.MCR-18-0185. Epub 2018 Sep 17.

PMID:
30224540
15.

TGFB1-driven mesenchymal stem cell-mediated NIS gene transfer.

Schug C, Urnauer S, Jaeckel C, Schmohl KA, Tutter M, Steiger K, Schwenk N, Schwaiger M, Wagner E, Nelson PJ, Spitzweg C.

Endocr Relat Cancer. 2019 Jan 1;26(1):89-101. doi: 10.1530/ERC-18-0173.

PMID:
30121623
16.

[Update of the S2k guidelines : Surgical treatment of benign thyroid diseases].

Musholt TJ, Bockisch A, Clerici T, Dotzenrath C, Dralle H, Goretzki PE, Hermann M, Holzer K, Karges W, Krude H, Kussmann J, Lorenz K, Luster M, Niederle B, Nies C, Riss P, Schabram J, Schabram P, Schmid KW, Simon D, Spitzweg C, Steinmüller T, Trupka A, Vorländer C, Weber T, Bartsch DK; Leitliniengruppe der CAEK.

Chirurg. 2018 Sep;89(9):699-709. doi: 10.1007/s00104-018-0653-y. Review. German.

PMID:
29876616
17.

[Hypothyroidism-when and how to treat?]

Koehler VF, Reincke M, Spitzweg C.

Internist (Berl). 2018 Jul;59(7):644-653. doi: 10.1007/s00108-018-0438-x. Review. German. Erratum in: Internist (Berl). 2018 Oct 25;:.

PMID:
29872890
18.

External Beam Radiation Therapy Enhances Mesenchymal Stem Cell-Mediated Sodium-Iodide Symporter Gene Delivery.

Schug C, Sievert W, Urnauer S, Müller AM, Schmohl KA, Wechselberger A, Schwenk N, Lauber K, Schwaiger M, Multhoff G, Wagner E, Nelson PJ, Spitzweg C.

Hum Gene Ther. 2018 Nov;29(11):1287-1300. doi: 10.1089/hum.2018.025. Epub 2018 May 3.

PMID:
29724129
19.

[Differentiated thyroid cancer - is less (therapy) more?]

Todica A, Ladurner R, Spitzweg C.

Dtsch Med Wochenschr. 2018 Apr;143(7):453-458. doi: 10.1055/s-0044-102192. Epub 2018 Apr 3. German.

PMID:
29614533
20.

Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors.

Aristizabal Prada ET, Heinzle V, Knösel T, Nölting S, Spöttl G, Maurer J, Spitzweg C, Angele M, Schmidt N, Beuschlein F, Stalla GK, Blaser R, Kuhn KA, Auernhammer CJ.

Endocr Relat Cancer. 2018 May;25(5):547-560. doi: 10.1530/ERC-17-0201. Epub 2018 Mar 21.

PMID:
29563190
21.

Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.

Jin XF, Spampatti MP, Spitzweg C, Auernhammer CJ.

Rev Endocr Metab Disord. 2018 Jun;19(2):145-158. doi: 10.1007/s11154-018-9443-6. Review.

PMID:
29464446
22.

Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies.

Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S, Ilhan H, Knösel T, Mayerle J, Reincke M, Bartenstein P.

Lancet Diabetes Endocrinol. 2018 May;6(5):404-415. doi: 10.1016/S2213-8587(17)30401-1. Epub 2017 Dec 8. Review.

PMID:
29229497
23.

EGFR-targeted nonviral NIS gene transfer for bioimaging and therapy of disseminated colon cancer metastases.

Urnauer S, Müller AM, Schug C, Schmohl KA, Tutter M, Schwenk N, Rödl W, Morys S, Ingrisch M, Bertram J, Bartenstein P, Clevert DA, Wagner E, Spitzweg C.

Oncotarget. 2017 Sep 16;8(54):92195-92208. doi: 10.18632/oncotarget.21028. eCollection 2017 Nov 3.

24.

Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.

Schmohl KA, Dolp P, Schug C, Knoop K, Klutz K, Schwenk N, Bartenstein P, Nelson PJ, Ogris M, Wagner E, Spitzweg C.

Thyroid. 2017 Dec;27(12):1534-1543. doi: 10.1089/thy.2017.0290. Epub 2017 Nov 10.

PMID:
29032724
25.

[Thyroid emergencies : Thyroid storm and myxedema coma].

Spitzweg C, Reincke M, Gärtner R.

Internist (Berl). 2017 Oct;58(10):1011-1019. doi: 10.1007/s00108-017-0306-0. Review. German.

PMID:
28939923
26.

EGFR Targeting and Shielding of pDNA Lipopolyplexes via Bivalent Attachment of a Sequence-Defined PEG Agent.

Morys S, Urnauer S, Spitzweg C, Wagner E.

Macromol Biosci. 2018 Jan;18(1). doi: 10.1002/mabi.201700203. Epub 2017 Sep 6.

PMID:
28877405
27.

Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study.

Baur J, Büntemeyer TO, Megerle F, Deutschbein T, Spitzweg C, Quinkler M, Nawroth P, Kroiss M, Germer CT, Fassnacht M, Steger U; German Adrenocortical Carcinoma Study Group.

BMC Cancer. 2017 Aug 4;17(1):522. doi: 10.1186/s12885-017-3506-z.

28.

Systemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes.

Urnauer S, Klutz K, Grünwald GK, Morys S, Schwenk N, Zach C, Gildehaus FJ, Rödl W, Ogris M, Wagner E, Spitzweg C.

J Gene Med. 2017 May;19(5). doi: 10.1002/jgm.2957.

PMID:
28423213
29.

Influence of Defined Hydrophilic Blocks within Oligoaminoamide Copolymers: Compaction versus Shielding of pDNA Nanoparticles.

Morys S, Krhac Levacic A, Urnauer S, Kempter S, Kern S, Rädler JO, Spitzweg C, Lächelt U, Wagner E.

Polymers (Basel). 2017 Apr 19;9(4). pii: E142. doi: 10.3390/polym9040142.

30.

Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer.

Vattai A, Akyol E, Kuhn C, Hofmann S, Heidegger H, von Koch F, Hermelink K, Wuerstlein R, Harbeck N, Mayr D, Spitzweg C, Toth B, Mahner S, Jeschke U, Ditsch N.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1637-1647. doi: 10.1007/s00432-017-2420-8. Epub 2017 Apr 13.

PMID:
28409272
31.

Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.

Schmohl KA, Gupta A, Grünwald GK, Trajkovic-Arsic M, Klutz K, Braren R, Schwaiger M, Nelson PJ, Ogris M, Wagner E, Siveke JT, Spitzweg C.

Oncotarget. 2017 May 16;8(20):33393-33404. doi: 10.18632/oncotarget.16499.

32.

Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany.

Wendler J, Kroiss M, Gast K, Kreissl MC, Allelein S, Lichtenauer U, Blaser R, Spitzweg C, Fassnacht M, Schott M, Führer D, Tiedje V.

Eur J Endocrinol. 2016 Dec;175(6):521-529.

PMID:
27926471
33.

Leveraging the immune system to treat advanced thyroid cancers.

French JD, Bible K, Spitzweg C, Haugen BR, Ryder M.

Lancet Diabetes Endocrinol. 2017 Jun;5(6):469-481. doi: 10.1016/S2213-8587(16)30277-7. Epub 2016 Oct 20. Review.

PMID:
27773653
34.

Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery.

Müller AM, Schmohl KA, Knoop K, Schug C, Urnauer S, Hagenhoff A, Clevert DA, Ingrisch M, Niess H, Carlsen J, Zach C, Wagner E, Bartenstein P, Nelson PJ, Spitzweg C.

Oncotarget. 2016 Aug 23;7(34):54795-54810. doi: 10.18632/oncotarget.10758.

35.

The added value of 68Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin.

Kazmierczak PM, Rominger A, Wenter V, Spitzweg C, Auernhammer C, Angele MK, Rist C, Cyran CC.

Eur Radiol. 2017 Apr;27(4):1676-1684. doi: 10.1007/s00330-016-4475-3. Epub 2016 Jul 19.

PMID:
27436022
36.

Fine Needle Aspiration in the Investigation of Thyroid Nodules.

Feldkamp J, Führer D, Luster M, Musholt TJ, Spitzweg C, Schott M.

Dtsch Arztebl Int. 2016 May 20;113(20):353-9. doi: 10.3238/arztebl.2016.0353. Review.

37.

Harnessing mesenchymal stem cell homing as an anticancer therapy.

Hagenhoff A, Bruns CJ, Zhao Y, von Lüttichau I, Niess H, Spitzweg C, Nelson PJ.

Expert Opin Biol Ther. 2016 Sep;16(9):1079-92. doi: 10.1080/14712598.2016.1196179. Epub 2016 Jun 13. Review.

PMID:
27270211
38.

New drugs for medullary thyroid cancer: new promises?

Spitzweg C, Morris JC, Bible KC.

Endocr Relat Cancer. 2016 Jun;23(6):R287-97. doi: 10.1530/ERC-16-0104. Epub 2016 May 16. Review.

PMID:
27185870
39.

Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene.

Urnauer S, Morys S, Krhac Levacic A, Müller AM, Schug C, Schmohl KA, Schwenk N, Zach C, Carlsen J, Bartenstein P, Wagner E, Spitzweg C.

Mol Ther. 2016 Aug;24(8):1395-404. doi: 10.1038/mt.2016.95. Epub 2016 May 9.

40.

Establishment of an Effective Radioiodide Thyroid Ablation Protocol in Mice.

Schmohl KA, Müller AM, Schwenk N, Knoop K, Rijntjes E, Köhrle J, Heuer H, Bartenstein P, Göke B, Nelson PJ, Spitzweg C.

Eur Thyroid J. 2015 Sep;4(Suppl 1):74-80. doi: 10.1159/000381019. Epub 2015 May 23.

41.

Life-threatening events in patients with pheochromocytoma.

Riester A, Weismann D, Quinkler M, Lichtenauer UD, Sommerey S, Halbritter R, Penning R, Spitzweg C, Schopohl J, Beuschlein F, Reincke M.

Eur J Endocrinol. 2015 Dec;173(6):757-64. doi: 10.1530/EJE-15-0483. Epub 2015 Sep 7.

PMID:
26346138
42.

Thyroid hormones and tetrac: new regulators of tumour stroma formation via integrin αvβ3.

Schmohl KA, Müller AM, Wechselberger A, Rühland S, Salb N, Schwenk N, Heuer H, Carlsen J, Göke B, Nelson PJ, Spitzweg C.

Endocr Relat Cancer. 2015 Dec;22(6):941-52. doi: 10.1530/ERC-15-0245. Epub 2015 Aug 25.

PMID:
26307023
43.

(124)I-PET Assessment of Human Sodium Iodide Symporter Reporter Gene Activity for Highly Sensitive In Vivo Monitoring of Teratoma Formation in Mice.

Lehner S, Lang C, Kaissis G, Todica A, Zacherl MJ, Boening G, Spitzweg C, Herbach N, Franz WM, Krause BJ, Steinhoff G, Bartenstein P, Hacker M, David R.

Mol Imaging Biol. 2015 Dec;17(6):874-83. doi: 10.1007/s11307-015-0857-1.

PMID:
25896817
44.

Quantification of in vitro mesenchymal stem cell invasion into tumor spheroids using selective plane illumination microscopy.

Rühland S, Wechselberger A, Spitzweg C, Huss R, Nelson PJ, Harz H.

J Biomed Opt. 2015 Apr;20(4):040501. doi: 10.1117/1.JBO.20.4.040501.

45.

Mesenchymal stem cell-mediated, tumor stroma-targeted radioiodine therapy of metastatic colon cancer using the sodium iodide symporter as theranostic gene.

Knoop K, Schwenk N, Schmohl K, Müller A, Zach C, Cyran C, Carlsen J, Böning G, Bartenstein P, Göke B, Wagner E, Nelson PJ, Spitzweg C.

J Nucl Med. 2015 Apr;56(4):600-6. doi: 10.2967/jnumed.114.146662. Epub 2015 Mar 5.

46.

[Advanced radioiodine-refractory differentiated thyroid cancer].

Spitzweg C, Auernhammer CJ, Geisler J, Böck S, Heinemann V, Bartenstein P, Göke B.

Dtsch Med Wochenschr. 2015 Feb;140(3):168-71. doi: 10.1055/s-0041-100196. Epub 2015 Feb 6. Review. German. No abstract available.

PMID:
25658401
47.

[Thyroid dysfunction in pregnancy].

Führer D, Mann K, Feldkamp J, Krude H, Spitzweg C, Kratzsch J, Schott M.

Dtsch Med Wochenschr. 2014 Oct;139(42):2148-52. doi: 10.1055/s-0034-1387300. Epub 2014 Oct 7. Review. German.

PMID:
25289925
48.

Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum.

Ilhan H, Fendler WP, Cyran CC, Spitzweg C, Auernhammer CJ, Gildehaus FJ, Bartenstein P, Angele MK, Haug AR.

Ann Surg Oncol. 2015 Jan;22(1):164-71. doi: 10.1245/s10434-014-3981-2. Epub 2014 Sep 5.

PMID:
25190113
49.

Best supportive care from the conservative/non-surgical perspective and its costs in the treatment of patients with advanced medullary thyroid cancer: results of a Delphi panel.

Kreissl MC, Jacob C, Führer D, Karges W, Luster M, Lux MP, Mann K, Mittendorf T, Schott M, Spitzweg C, Schmoll HJ.

Oncol Res Treat. 2014;37(6):316-22. doi: 10.1159/000362613. Epub 2014 May 12.

PMID:
24903762
50.

Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.

Spitzweg C, Bible KC, Hofbauer LC, Morris JC.

Lancet Diabetes Endocrinol. 2014 Oct;2(10):830-42. doi: 10.1016/S2213-8587(14)70051-8. Epub 2014 Jun 2. Review.

PMID:
24898835

Supplemental Content

Loading ...
Support Center